| [1] |
褚杰，杜平，何晨,等.载脂蛋白B/A-1比值联合颈动脉斑块性质检查在冠心病患者危险性预测中的价值[J].实用临床医药杂志, 2017, 21(11): 35-37.
|
| [2] |
Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels[J]. Journal of internal medicine, 2006, 259(5): 437-446.
|
| [3] |
Sniderman AD, Marcovina SM. Apolipoprotein A1 and B[J]. Clinics in Laboratory Medicine, 2006, 26(4): 733-750.
|
| [4] |
Steffen BT, Guan W, Remaley AT, et al. Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants[J]. Journal of Clinical Lipidology, 2017, 11(5): 1181.
|
| [5] |
宫利平.血清Apo-A1与Apo-B比值与青年女性进展型缺血性脑卒中患者颈动脉粥样硬化发生率的关联性[J].内蒙古医学杂志, 2018(3).
|
| [6] |
Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy[J]. Journal of Internal Medicine, 2004, 255(2): 188-205.
|
| [7] |
Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment[J]. Clinica E Investigacion En Arteriosclerosis, 2004, 16(1): 38-38.
|
| [8] |
Fodor JG, Frohlich JJ, Genest JJG, et al. Recommendations for the management and treatment of dyslipidemia Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias[J]. Cmaj, 2000, 162(10): 1441-1447.
|
| [9] |
Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy[J]. Circulation, 2002, 107(20): 2526.
|
| [10] |
Lewis GF, Rader DJ. New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport[J]. Circulation Research, 2005, 96(12): 1221-1232.
|
| [11] |
李灏，蔡勇，黄金波,等.缺血性脑卒中患者载脂蛋白及血浆脂蛋白相关磷脂酶A2与TOAST病因分型的研究[J].临床荟萃, 2018, 33(4): 298-301.
|
| [12] |
Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome[J]. Current Opinion in Lipidology, 2007, 18(6): 633-637.
|
| [13] |
Kim BJ, Hwang ST, Sung KC, et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions[J]. Clinical Chemistry, 2005, 51(12): 2257-2263.
|
| [14] |
Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic Factors and Recurrent Coronary Events[J]. Circulation, 1999, 99(19):2517-2522.
|
| [15] |
GottoAM, Whitney, Stein EA, et al. Ralation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atheroscle-rosis Prevention study (AFCAPS/TexCAPS)[J].Circulation 2000, 101 :477-484.
|
| [16] |
Pedersen TR, Olsson AG, Færgeman O, et al. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)[J]. Atherosclerosis Supplements, 2004, 5(3): 1453-1460.
|
| [17] |
Qureshi AI, Giles WH, Croft J B, et al. Apolipoproteins A-1 and B and the likelihood of non-fatal stroke and myocardial infarction—data from The Third National Health and Nutrition Examination Survey[J]. Medical Science Monitor International Medical Journal of Experimental & Clinical Research, 2002, 8(5): CR311.
|
| [18] |
Bhatia M, Howard SC, Clark TG, et al. Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack[J].Cerebrovascular Diseases, 2006, 21(5-6): 323-328.
|
| [19] |
Curb JD, Abbott RD, Rodriguez BL, et al. High Density Lipoprotein Cholesterol and the Risk of Stroke in Elderly MenThe Honolulu Heart Program[J]. American Journal of Epidemiology, 2004, 160(2): 150.
|
| [20] |
Witt BJ, Brown RD, Jacobsen SJ, et al. A Community-Based Study of Stroke Incidence after Myocardial Infarction[J]. Annals of Internal Medicine, 2005, 143(11): 785-792.
|
| [21] |
Makaridze Z, Giorgadze E, Asatiani K. Apolipoprotein B/apolipoprotein A-I ratio in relation to the metabolic syndrome, its components, total cholesterol and low-density lipoprotein cholesterol in the population of Georgia[J]. Georgian Medical News, 2014: 32-39.
|
| [22] |
Jadhav UM, Kadam NN. Apolipoproteins: correlation with carotid intimamedia thickness and coronary artery disease[J]. Atherosclerosis, 2004, 7(3): 370-375.
|
| [23] |
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge[J]. Clinical Chemistry, 1972, 18(6): 499.
|
| [24] |
van Lennep JE, Westerveld HT, van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events[J]. Arteriosclerosis Thrombosis & Vascular Biology, 2000, 20(11): 2408.
|
| [25] |
Kirkham TC. Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia—NEJM[J]. New England Journal of Medicine. 2005, 353(20): 2121-2134.
|
| [26] |
Caslake MJ, Stewart G, Day SP, et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia[J]. Atherosclerosis, 2003, 171(2): 245-253.
|
| [27] |
Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study[J]. Current Medical Research & Opinion, 2005, 21(11): 1865-1874.
|
| [28] |
Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study[J]. Journal of Internal Medicine, 2010, 259(3): 259-266.
|
| [29] |
Gyárfás I, Keltai M, Salim Y. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study[J]. Orvosi Hetilap, 2006, 147(15): 675.
|
| [30] |
Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study[J]. Acc Current Journal Review, 2002, 11(3): 34.
|
| [31] |
Makaridze Z, Giorgadze E, Asatiani K. Apolipoprotein B/apolipoprotein A-I ratio in relation to the metabolic syndrome, its components, total cholesterol and low-density lipoprotein cholesterol in the population of Georgia[J]. Georgian Medical News, 2014: 32-39.
|
| [32] |
Chyu KY, Dimayuga PC, Shah PK. Vaccine against arteriosclerosis: an update[J]. Therapeutic Advances in Vaccines, 2017, 5(2): 39.
|